OMCL Omnicell Inc.

Allegheny General Hospital Partners with Omnicell to Automate Sterile Compounding

Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced that Allegheny General Hospital, Pittsburgh, Pa., part of Allegheny Health Network (AHN), has selected Omnicell’s Central Pharmacy IV Compounding Service, a comprehensive, turnkey approach for insourcing some sterile compounding operations.

Nearly one out of ten IVs are not prepared within guidelines1 using manual processes and contamination is one of the most frequent errors2. Omnicell’s Central Pharmacy IV Compounding Service addresses this issue with the combination of advanced robotic technology, data and expertly trained pharmacy technician staff to provide a streamlined path for hospitals to insource their sterile compounding, enabling them to enhance patient safety and reduce pharmacy outsourcing costs.

“Sterile compounding is one of the biggest challenges for hospital pharmacies. Many hospitals choose to outsource their compounding needs, which can be expensive and unreliable at times. However, moving to an insourcing model requires technology and trained staff,” said Laura Mark, vice president, pharmacy, AHN. “Omnicell’s Central Pharmacy IV Compounding Service provides hospitals the tools and resources they need to insource and automate their sterile compounding, creating a safer, more accurate and, ultimately, more cost-effective IV compounding operation.”

“The Central Pharmacy IV Compounding Service is part of Omnicell’s autonomous pharmacy vision and our pursuit towards 100 percent of IV preparations going through IV automation technology,” said Douglas Descalzi, vice president and general manager, IV Solutions and Robotic Dispensing Systems, Omnicell. “The service enables hospitals to not just automate compounding, but to adopt and optimize the technology.”

About Allegheny Health Network

Allegheny Health Network (AHN) is an integrated health system dedicated to providing exceptional care to people in our communities. Our patient-centered approach to care means a greater focus on coordinated health and wellness services, as well as being accountable and responsive to patients from start to finish. For more information visit: .

About Omnicell

Since 1992, Omnicell has been committed to transforming the pharmacy care delivery model to dramatically improve outcomes and lower costs. Through the vision of the autonomous pharmacy, a combination of automation, intelligence, and expert services, powered by a cloud data platform, Omnicell supports more efficient ways to manage medications across all care settings. Over 6,000 facilities worldwide use Omnicell automation and analytics solutions to help increase operational efficiency, reduce medication errors, deliver actionable intelligence, and improve patient safety. More than 40,000 institutional and retail pharmacies across North America and the United Kingdom leverage Omnicell's innovative medication adherence and population health solutions to improve patient engagement and adherence to prescriptions, helping to reduce costly hospital readmissions. To learn more, visit .

1 Flynn EA, Pearson RE, Barker K. Observational study of accuracy in compounding i.v. admixtures at five hospitals. Am J Health-Syst Pharm. 1997;54(8):904-12

2

OMCL-G

EN
21/01/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Omnicell Inc.

Omnicell Inc: 2 directors

Two Directors at Omnicell Inc sold/bought 11,951 shares at between 73.144USD and 73.760USD. The significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over ...

OMNICELL increases its risk exposure and slightly lowers to Neutral

OMNICELL (US), a company active in the Medical Equipment industry, now shows a lower overall rating. The independent financial analyst theScreener confirms the fundamental rating of 3 out of 4 stars. However, the market behaviour deterioration triggered a risk requalification, which can be thus described as moderately risky. theScreener believes that increased risk justifies the general evaluation downgrade to Neutral. As of the analysis date February 23, 2021, the closing price was USD 130.05 a...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Allegheny General Hospital Partners with Omnicell to Automate Sterile ...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced that Allegheny General Hospital, Pittsburgh, Pa., part of Allegheny Health Network (AHN), has selected Omnicell’s Central Pharmacy IV Compounding Service, a comprehensive, turnkey approach for insourcing some sterile compounding operations. Nearly one out of ten IVs are not prepared within guidelines1 using manual processes and contamination is one of the most frequent errors2. Omnicell’s Central P...

 PRESS RELEASE

Omnicell Reports Results for Second Quarter 2019

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced results for its second quarter ended June 30, 2019. GAAP Results GAAP revenues for the second quarter of 2019 were $217.4 million, up $28.7 million, or 15.2% from the second quarter of 2018. GAAP revenues for the six months ended June 30, 2019 were $419.9 million, up $48.6 million, or 13.1%, from the six months ended June 30, 2018. Second quarter 2019 GAAP net income as reported was $16.0 m...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch